Chinese Pharmaceutical Innovation Gaining Presence in Japan

According to the news “中国製薬、日本でもじわり存在感 | AnswersNews (” released by AnswersNews on 22/Sep/2023, Chinese pharmaceutical innovations are gaining prominence in Japan. In 2021, the anti-cancer drug “Hiyasta” developed in China was approved in Japan. In September 2023, Shanghai-based biotech firm, Haihe Biopharma, applied for gumarontinib in Japan. Takeda Pharmaceutical Company acquired the development and sales rights for the VEGFR inhibitor drug, fruquintinib, from Hong Kong’s HUTCHMED, aiming for obtaining approvals in Japan, the US, and Europe. Chinese pharmaceutical industry is rapidly growing in new drug development. In 2019, BeiGene’s BTK inhibitor, “Brukinsa”, became the first China-developed drug to gain approval in the US, and it is now approved in over 65 countries. The Chinese government strategy called “Made in China 2025” which was initiated in 2015, prioritized the biopharmaceutical sector and promoted innovation in new drug development. As of 2023, the Chinese pharmaceutical market ranks second globally, and four Chinese companies are listed in the top 50 global pharmaceutical companies. Among these companies, Jiangsu Hengrui Pharmaceuticals has marked its footprint in Japan, becoming the first Chinese company to initiate pharmaceutical sales there. Japanese pharmaceutical companies are also actively adopting Chinese innovations. Following Takeda’s agreement with HUTCHMED. EA Pharma has initiated joint research with Nanjing-based TransThera Sciences. In summary, Chinese pharmaceutical innovation is increasing its presence in Japan, and Japanese pharmaceutical companies are intensifying their efforts to incorporate Chinese innovations.